U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07369154) titled '52-week Open Label Safety-Tolerability Study' on Dec. 26, 2025.
Brief Summary: Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: LB-102
LB-102 flexible dosing 50 mg - 100 mg
Recruitment Status: NOT_YET_RECRUITING
Sponsor: LB Pharmaceuticals Inc.
Disclaimer: Curated by HT Syndication....